William Lewis Sells 13,396 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 13,396 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $147.79, for a total transaction of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $44,512,131.15. The trade was a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

William Lewis also recently made the following trade(s):

• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total transaction of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total transaction of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total value of $561,349.91.
• On Wednesday, January 7th, William Lewis sold 2,357 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $412,639.99.
• On Tuesday, January 6th, William Lewis sold 4,096 shares of Insmed stock. The stock was sold at an average price of $173.33, for a total value of $709,959.68.
• On Thursday, December 18th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $166.97, for a total value of $1,786,412.03.

Insmed Stock Performance

Shares of Insmed stock opened at $146.17 on Friday. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The firm’s 50-day moving average is $170.16 and its 200 day moving average is $161.17. The stock has a market cap of $31.17 billion, a price-to-earnings ratio of -23.61 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of INSM. CI Investments Inc. grew its stake in shares of Insmed by 43.8% during the 4th quarter. CI Investments Inc. now owns 2,477 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 755 shares during the period. Rossby Financial LCC grew its position in Insmed by 240.4% during the fourth quarter. Rossby Financial LCC now owns 1,028 shares of the biopharmaceutical company’s stock valued at $179,000 after buying an additional 726 shares during the period. Federation des caisses Desjardins du Quebec grew its position in Insmed by 14.5% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 15,142 shares of the biopharmaceutical company’s stock valued at $2,634,000 after buying an additional 1,919 shares during the period. DRW Securities LLC bought a new stake in Insmed during the fourth quarter valued at approximately $478,000. Finally, Insigneo Advisory Services LLC grew its position in Insmed by 10.2% during the fourth quarter. Insigneo Advisory Services LLC now owns 2,641 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 245 shares during the period.

Analysts Set New Price Targets

INSM has been the topic of several analyst reports. Morgan Stanley upped their price objective on Insmed from $157.00 to $162.00 and gave the company an “equal weight” rating in a research report on Friday, January 30th. Guggenheim lowered their price target on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Jefferies Financial Group set a $269.00 price objective on Insmed in a research report on Wednesday, December 10th. Wells Fargo & Company set a $195.00 target price on Insmed in a research report on Thursday, December 18th. Finally, Wolfe Research set a $167.00 target price on shares of Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $204.24.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Zacks expects Insmed to beat upcoming earnings, which could support the stock if results and guidance meet those expectations. Insmed (INSM) Expected to Beat Earnings Estimates
• Positive Sentiment: Brokerage coverage remains constructive — the consensus rating is around “Buy” with several firms assigning strong-buy/outperform calls and an average price target well above current levels, which supports medium-term upside. Insmed Given Average Rating of “Buy” by Brokerages
• Neutral Sentiment: Short-interest reports in the feeds show anomalous/zero values and NaN changes — data appears unreliable. This reduces clarity on whether rising short interest is a meaningful driver today. (Treat short-interest signals with caution.)
• Neutral Sentiment: Trading volume is modestly above average, indicating elevated attention but not an extreme flow that would by itself explain a sustained move.
• Negative Sentiment: CEO William Lewis disclosed the sale of 13,396 shares (and has sold several tranches in recent weeks). High-profile insider selling is being read as a bearish signal by some investors and likely contributed to downward pressure. Insmed CEO William Lewis Sells 13,396 Shares
• Negative Sentiment: Coverage flagged “possible bearish signals” tied to insider disposals, amplifying investor concern and short-term selling pressure. Possible Bearish Signals With Insmed Insiders Disposing Stock

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.